Vivos Therapeutics (VVOS) Misses Q2 EPS by 16c

Vivos Therapeutics (NASDAQ: VVOS) reported Q2 EPS of ($0.55), $0.16 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $3.78 million.

For earnings history and earnings-related data on Vivos Therapeutics (VVOS) click here.

You May Also Be Interested In

• SolarEdge (SEDG) PT Lowered to $31 at Jefferies, 'We see shares as an unappealing short, not a compelling long'
• Nvidia to start employee-funded U.S. political action committee called NVPAC - Reuters
• Dollar General stock jumps on earnings beat and raised guidance